Editor mode — upload your images, then download the file.
Suvendu Ojha

Suvendu Ojha

Ph.D. in Biotechnology (Microbiology) · Research Associate-I
Bacterial Cell Division & Antimicrobial Resistance Lab, BRIC-Institute of Life Sciences, Bhubaneswar

I work on how bacterial pathogens survive antibiotics — the transport, signalling, metabolic and regulatory physiology behind resistance and tolerance, and what it takes to reverse it.

Schematic. Amber = antibiotic. Drag to rotate, tap a cell to divide.
7
Published papers
4
First / co-first
2
Patents (1 granted)
5
Researchers mentored
About

A microbiologist working on why antibiotics stop working.

Icompleted my PhD at BRIC-Institute of Life Sciences, Bhubaneswar, in 2025 and continue there as a Research Associate. My doctoral work asked how Staphylococcus aureus uses multidrug efflux systems to survive antibiotic exposure, how those systems are wired into global transcriptional regulators such as MgrA, and whether that machinery can be switched off pharmacologically. Answering it meant building the whole chain of evidence myself — screening approved-drug and LOPAC libraries, tracing hits back to the regulators controlling pump expression, measuring direct protein–ligand binding by calorimetry and spectroscopy, reading out membrane energetics and biofilm consequences by flow cytometry and confocal microscopy, and finally asking in murine infection whether restored susceptibility survives contact with a host. Two compound series from that work became Indian patents, one granted in 2026.

My interests now sit a layer above any single pump. What holds my attention is the question of why a genetically susceptible organism can still survive treatment, and the physiology that decides it: nucleotide second messengers — c-di-AMP, c-di-GMP, (p)ppGpp — and the growth, stress and persistence programmes they control; bacterial metabolism and the metabolic adaptations that accompany infection, including metabolic vulnerabilities that might themselves be drug targets; antibiotic tolerance and persistence as phenomena genuinely distinct from resistance; and biofilms as a physiological state rather than a phenotype, particularly where biofilm physiology, metabolism and reduced susceptibility meet in chronic infection.

I am equally drawn to polymicrobial infection — how species compete, cooperate, signal and exchange metabolites when they share a host niche, and how any of that alters antibiotic susceptibility. Alongside it sits the regulatory biology that connects virulence, stress responses and survival: quorum sensing, global regulators, and the networks that let a cell change what it is doing in response to what is happening around it.

Running through all of it is a preference for mechanistic questions that keep a translational end attached. Efflux inhibitors, potentiators and adjuvants, metabolic and signalling targets, and repurposed compounds are the fastest route from a finding to something usable — and, just as importantly, they force honesty about whether a proposed mechanism actually matters in a living host. Alongside my own projects I have trained five doctoral and master's researchers at the bench, which I have come to enjoy more than I expected.

Research

Research interests.

Three connected themes. The questions I find most interesting sit where they overlap.

01

Resistance, tolerance and chronic infection

  • Mechanisms of antimicrobial resistance, and how it emerges and evolves
  • Multidrug efflux systems and the global regulators controlling their expression
  • Antibiotic tolerance and persistence as distinct from resistance
  • Biofilm formation, maturation and biofilm-associated tolerance
02

Signalling, metabolism and microbial communities

  • Nucleotide second messengers — c-di-GMP, c-di-AMP, (p)ppGpp — and the growth, stress and persistence programmes they control
  • Metabolic adaptation during infection, and metabolic vulnerabilities as potential targets
  • Polymicrobial interaction: competition, cooperation, cross-species signalling and metabolic exchange
  • Pathogenesis, virulence regulation and quorum sensing
03

Antimicrobial discovery and therapeutic strategy

  • Identification of novel antimicrobial targets
  • Efflux pump inhibitors, potentiators and adjuvants
  • Repurposing approved compounds against resistant pathogens
  • Combination therapies aimed at resistance, tolerance and biofilm survival
Training

Education and research positions.

September 2025 — Present

Research Associate-I

Bacterial Cell Division & Antimicrobial Resistance Lab, BRIC-Institute of Life Sciences, Bhubaneswar · Supervisor: Dr. Tushar Kant Beuria

Preclinical evaluation of a montelukast–moxifloxacin combination against MRSA, covering antimicrobial efficacy and PK/PD. Investigating the mechanisms behind combination activity — efflux suppression, bacterial clearance, host inflammatory response and tissue drug exposure during systemic infection — and screening dual-acting efflux pump and biofilm inhibitors as adjunctive strategies.

July 2019 — September 2025

Ph.D. in Biotechnology (Microbiology)

Degree awarded by the Regional Centre for Biotechnology (RCB), Faridabad — a DBT institution of national importance. Research carried out at BRIC-Institute of Life Sciences, Bhubaneswar · Supervisor: Dr. Tushar Kant Beuria

Thesis: Targeting Efflux-Mediated Drug Resistance in S. aureus to Enhance the Therapeutic Potential of Existing Antibiotics. Viva voce 22 September 2025; degree awarded 19 December 2025. Held CSIR Junior and Senior Research Fellowships throughout.

2016 — January 2019

M.Sc. Botany — specialisation in Biochemistry

School of Life Sciences, Sambalpur University, Odisha · Supervisor: Prof. Binata Nayak

Thesis: Investigation of the Anti-Urease Potential of Mentha piperita.

2013 — May 2016

B.Sc. Botany

Udayanath Autonomous College of Science and Technology, Cuttack
Publications

Peer-reviewed work.

Newest first, author position in bold. Manuscripts in preparation are listed at the end.

Manuscript
in preparation
Adapalene functions as a broad-acting transcriptional repressor of efflux pumps to sensitise MRSA to β-lactam antibiotics

Ojha S, Beuria TK

Moves the intervention point from the pump itself to the transcription that builds it.

In preparationFirst author
Manuscript
in preparation
Repurposing amlodipine as an efflux pump inhibitor to restore β-lactam efficacy in methicillin-resistant Staphylococcus aureus

Ojha S, Beuria TK

A widely prescribed cardiovascular drug tested as a resistance-breaking adjuvant in MRSA.

In preparationFirst author
Manuscript
in preparation
Inhibition of efflux pumps in clinically relevant resistant strains by marine cyanobacterial metabolites nhatrangin A and γ-butyrolactone: an integrated in vitro and in silico approach

Parvin N, Ojha S, Beuria TK, Rath J

Natural-product chemistry as a source of efflux inhibitors, screened in clinically relevant resistant isolates alongside docking analysis.

In preparationCollaborative

Full record on Google Scholar · ORCID 0000-0003-0439-5065

Patents

Intellectual property.

Both arising directly from my doctoral screening and mechanism work.

Patent certificateIN 599299
A formulation to inhibit the growth of multidrug-resistant S. aureus

Suvendu Ojha, Tushar Kant Beuria · Patentee: Institute of Life Sciences

Filed 20 Aug 2024 · Application 202431062787 IN 599299 Granted 14 Aug 2026
Patent applicationIN 2025
53455
Pharmaceutical compositions comprising sertaconazole or oxiconazole as efflux pump inhibitors for treating multidrug-resistant Staphylococcus aureus infections

Suvendu Ojha, Tushar Kant Beuria

Provisional · Filed 2025 IN 202531053455 Pending
Skills

What I run at the bench.

From primary screen to in vivo validation, with the biophysics and imaging in between.

01

Screening & discovery

FDA-approved and LOPAC library screening for efflux, biofilm and combination activity, with the analysis pipelines and hit-triage criteria behind them.

02

Susceptibility & synergy

MIC and MBC to CLSI/EUCAST, E-test, checkerboard synergy, growth curves, resazurin viability, time-kill kinetics, and clinical isolate panels.

03

Molecular biology & expression

Cloning, recombinant expression, Western blotting, qRT-PCR profiling of regulators and their targets, and EMSA for protein–DNA interaction.

04

Protein biochemistry & biophysics

Protein purification, circular dichroism, isothermal titration calorimetry and fluorimetric protein–ligand binding — resolving where a compound actually acts.

05

Biofilm & advanced microscopy

Formation and dispersion assays, CLSM and STED with WGA-FITC, SYPRO Ruby, DAPI and acridine orange, plus SEM of matrix architecture.

06

Flow cytometry

BD Accuri C6 Plus and Beckman Coulter CytoFLEX — SYTO9/PI viability and DiOC2 membrane potential to separate bactericidal from bacteriostatic action.

07

Mammalian cell culture

A549 and HEK293T with STR authentication and mycoplasma testing; MTT cytotoxicity and CC₅₀ determination for safety profiling.

08

In vivo infection models

Murine S. aureus skin and systemic infection, G*Power sample sizing, CFU/g tissue burden, and pharmacodynamic readouts of combination therapy.

09

Statistics & experimental design

GraphPad Prism and Excel for ANOVA, regression and survival analysis, with power analysis to keep in vivo work adequately powered and properly controlled.

10

Biosafety & containment

BSL-2 and BSL-3 practice with strict protocol adherence, including COVID-19 diagnostic operations and handling of highly pathogenic organisms.

Awards

Awards and fellowships.

National fellowships, and recognition for the work presented at conferences.

Best Poster Award

National Symposium on One Health · BRIC-ILS

11–12 September 2026 — “Montelukast restores fluoroquinolone susceptibility in multidrug-resistant S. aureus by modulating the PknB–RsbU–MgrA regulatory axis.” BRIC-Institute of Life Sciences, Bhubaneswar.

Best Poster Award

MECH2MED-2026 · IIT Kharagpur

20–22 February 2026 — International Conference on Emerging Trends in Disease Biology: Mechanism to Medicine, Department of Bioscience & Biotechnology, IIT Kharagpur.

CSIR-NET (JRF) — All India Rank 77

Council of Scientific & Industrial Research

2019 — national doctoral fellowship examination. Held JRF and subsequently SRF through the PhD.

GATE Life Sciences — All India Rank 745

Graduate Aptitude Test in Engineering

2018 — national postgraduate and doctoral entrance examination, India.

Targeting Efflux Machinery to Combat AMR

Poster · SRM University Delhi-NCR

18–20 March 2024 — 3rd International Conference on Antimicrobial Resistance, Novel Drug Discovery and Vaccine Development, Sonepat.

Targeting Efflux Machinery to Combat AMR

Poster · QUAD mini-symposium

27 April 2024 — Quarterly Union for Academic Discourse, BRIC-Institute of Life Sciences, Bhubaneswar.

Service

Mentorship, peer review and professional activity.

Training researchers at the bench, reviewing for journals, speaking, and the societies I belong to.

Mentorship

  • Three PhD students — BRIC-Institute of Life Sciences, BhubaneswarSince Sep 2022 · two since Aug 2025
  • Two MSc thesis students — Ramadevi Women's University and KIIT, BhubaneswarJan — Jun 2022 · Feb — Jul 2026
  • Bench training — experimental design, laboratory technique, troubleshooting and interpretation of experimental dataOngoing

Journal peer review

  • BMC Microbiology — Springer NaturePeer reviewer · 1 manuscript, 2026
  • Naunyn-Schmiedeberg's Archives of Pharmacology — Springer NaturePeer reviewer · 1 manuscript, 2026

Invited talks

  • Career counselling programme — Department of Botany, Kendrapara Autonomous College, Odisha17 February 2026

Societies & networks

  • ESCMID — European Society of Clinical Microbiology and Infectious DiseasesLMIC member
  • BSAC — British Society for Antimicrobial ChemotherapyMember
  • ASM — American Society for MicrobiologyGlobal Outreach Student Member, 2026
  • Futures AMR Network (FAN) — UKRI-supported transdisciplinary AMR research networkMember
Correspondence

Get in touch.

Bacterial Cell Division & Antimicrobial Resistance Lab
BRIC-Institute of Life Sciences
Nalco Square, Bhubaneswar, Odisha 751023
India

Send an email

CV and publication list available on request.

References

Academic referees.

All three are at BRIC-Institute of Life Sciences, Bhubaneswar.

Dr. Tushar Kant Beuria

PhD Supervisor · Scientist-F

Bacterial Cell Division & Antimicrobial Resistance Lab

tkbeuria@ils.res.in

Dr. Narottam Acharya

Scientific Advisor · Scientist-G

Genome Instability Laboratory

narottam_acharya@ils.res.in

Dr. Soma Chattopadhyay

Doctoral Advisory Committee · Scientist-G

Molecular Virology Laboratory

soma@ils.res.in